Affymax

Affymax is a biopharmaceutical company founded in 2001 with a focus on pioneering innovative therapies for life-threatening conditions. Their flagship product candidate, peginesatide (previously known as Hematide™), has completed Phase 3 trials for treating anemia in chronic kidney disease (CKD) patients. The company has recently received a $42.00M Venture Round investment on March 3, 2009 from investors Bessemer Venture Partners, Sprout Group, ProQuest. Affymax's ambition to enhance anemia treatment for CKD patients underlines its positioning in the Biopharma, Biotechnology, and Health Care industries. The company's current focus is on obtaining approval from the U.S. Food and Drug Administration (FDA) for peginesatide to address anemia in adult CKD patients on dialysis.